^
    Back
    Association details:
    Biomarker:FCGR2A mutation
    Cancer:Follicular Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

    Published date:
    11/01/2017
    Excerpt:
    This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma....Overall, 62/65 patients (95%) responded (Table 3). The CR rate was 72% [95% confidence interval (CI), 60% to 83%...The FCGR3A and FCGR2A genotypes had similar CR rates (Cochran–Armitage trend test,P=0.55 andP=0.31, respectively).
    DOI:
    10.1093/annonc/mdx496
    Trial ID:
    NCT01145495